KAS
NBIX icon

Kestra Advisory Services’s Neurocrine Biosciences NBIX Stock Holding History

Kestra Advisory Services’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-373
Closed -$52.9K – 3941
2025
Q4 		$52.9K Buy
+373
New +$54K ﹤0.01% 3900
2024
Q3 		– Sell
-1,723
Closed -$237K – 2677
2024
Q2 		$237K Buy
1,723
+19
+1% +$2.61K ﹤0.01% 2286
2024
Q1 		$235K Buy
+1,704
New +$233K ﹤0.01% 2167
2023
Q1 		– Sell
-3,183
Closed -$380K – 2234
2022
Q4 		$380K Buy
+3,183
New +$373K ﹤0.01% 1567

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kestra Advisory Services's NBIX Position: Q1 2026 in Review

Kestra Advisory Services sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 373 shares — an estimated $52.9K sold.

Kestra Advisory Services first reported a position in NBIX in Q4 2022 and held it in 4 quarters. The position peaked at $380K in Q4 2022. 700 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Kestra Advisory Services reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Kestra Advisory Services sold 373 Neurocrine Biosciences shares in Q1 2026, an estimated $52.9K.
  • Kestra Advisory Services first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 4 quarters.
  • Kestra Advisory Services's Neurocrine Biosciences position peaked at $380K in Q4 2022.
  • 700 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.